Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

  title={Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies},
  author={Maen A. Hussein and Marina Maglakelidze and Donald A. Richards and Marielle Sabatini and Todd A Gersten and Keith A. Lerro and Ivan Sinielnikov and Alexander I. Spira and Yili Lu Pritchett and Joyce M. Antal and Rajesh K. Malik and J Thaddeus Beck},
  journal={Cancer Management and Research},
  pages={6207 - 6218}
Purpose Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression (CIM) by protecting hematopoietic stem and progenitor cells and immune system function from chemotherapy-induced damage (myeloprotection). Here, we investigated the myeloprotective effects of trilaciclib among patients at increased risk of CIM. Patients and Methods Data were pooled from three randomized, double-blind, placebo-controlled, phase… 

Figures and Tables from this paper

Small Cell Lung Cancer, Version 2.2022
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment,
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
The second year of the COVID-19 pandemic had no adverse effect on the number of new drug approvals by the US Food and Drug Administration (FDA), and 2021 belongs to the most successful FDA years.
Cytokinetic-driven myeloprotection after cytotoxic chemotherapy: from an old idea to a new clinical approach
Tilaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, has been studied and it has been demonstrated in several clinical trials to reduce the incidence of myelotoxicity in small-cell lung cancer patients treated with chemotherapy or chemo-immunotherapy.


Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Compared with placebo, the addition of trilaciclib prior to topotecan for the treatment of patients with previously treated ES-SCLC improves the patient experience of receiving chemotherapy, as demonstrated by a reduction in chemotherapy-induced myelosuppression, improved safety profile, improved quality of life and no detrimental effects on antitumor efficacy.
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Tilaciclib demonstrated an improvement in the patient's tolerability of chemotherapy as shown by myelopreservation across multiple hematopoietic lineages resulting in fewer supportive care interventions and dose reductions, improved safety profile, and no detriment to antitumor efficacy.
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial
Compared with placebo, trilaciclib administered prior to E/P/A improved patients' experience of receiving treatment for ES‐SCLC, as shown by reduced myelosuppression, and improved HRQoL and safety profiles.
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
Despite the various methods used to address CIM, and the patient-focused approach of oncologists, the real-world impact of CIM on patients is substantial and effective prevention and treatment for this condition are important.
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
G1T28 is described, a novel potent and selective CDK4/6 inhibitor that transiently and reversibly regulates the proliferation of murine and canine bone marrow hematopoietic stem and progenitor cells and provides multilineage protection from the hematologic toxicity of chemotherapy.
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group.
  • I. Ray-Coquard, A. Le Cesne, J. Blay
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
This risk index could be useful to identify patients at high risk for chemotherapy-induced SARRT who might be appropriate candidates for prophylactic erythropoietin treatment.
Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
CIT incidence was high, especially among patients receiving gemcitabine-based regimens, and the costs of CIT-related care were substantial, and interventions aimed at identifying and targeting high-risk patients for preventative measures may yield substantial clinical and economic benefits.
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Dose delays, dose reductions, and reduced RDI were common, and dose delays ≥ 7 days and high RDIwere significantly associated with decreased mortality, and these results can help identify potential risk factors and characterize the effect of chemotherapy dose modification strategies on mortality.
Hemopoietic reserve in the older cancer patient: clinical and economic considerations.
It is recommended that patients aged 70 and older receiving combination chemotherapy of dose-intensity comparable to CHOP be routinely treated with myelopoietic growth factor, to prevent costly complications such as neutropenic infections and functional dependence.